BioSpace News Archive

R1 RCM Inc. announced that Rush University System for Health has entered into a strategic partnership to achieve revenue cycle performance excellence and accelerate innovation in healthcare.

Research teams will use stem cell and gene editing technologies to advance NK cell-based therapies for cancer

Vericel Corporation announced that Gerard Michel, CFO, will present a company overview at the 22nd Annual Needham Growth Conference in New York on Wednesday, January 15, 2020, at 12:00pm Eastern Time.

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced CBX-12 (alphalex™-exatecan) as the new lead development program.

Karuna Therapeutics, Inc. announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will present at the 38th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA.

Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.

Revance Therapeutics, Inc., a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, provided a corporate and product pipeline update and shared anticipated milestones for 2020.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today confirmed that it will operate a main floor Exhibitor Booth at The CAMEX - NACS Campus Market Expo 2020 (“NACS Tradeshow”),

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share payments over the next four years.

Gencove’s flagship product is its low-pass whole genome sequencing platform, which is a technology that has the potential to more accurately assess the genetic potential of an animal earlier in its life.